Literature DB >> 23845720

Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes.

Joaquín Burgos1, Manel Luján, Maria Nieves Larrosa, Dionísia Fontanals, Guadalupe Bermudo, Ana Maria Planes, Mireia Puig, Jordi Rello, Vicenç Falcó, Albert Pahissa.   

Abstract

Pneumococcal serotypes are one of the main determinants of pneumococcal disease severity; however, data about their implication in respiratory failure are scarce. We conducted an observational study of adults hospitalised with invasive pneumococcal pneumonia to describe the host- and pathogen-related factors associated with respiratory failure. Of 1258 adults with invasive pneumococcal disease, 615 (48.9%) had respiratory failure at presentation. Patients with respiratory failure were older (62.1 years versus 55.4 years, p<0.001) and had a greater proportion of comorbid conditions. They also had a greater proportion of septic shock (41.7% versus 6.1%, p<0.001), required admission to the intensive care unit more often (38.4% versus 4.2%, p<0.001) and had a higher mortality (25.5% versus 3.5%, p<0.001). After adjustment, independent risk factors for respiratory failure were: age >50 years (OR 1.63, 95% CI 1.15-2.3), chronic lung disease (OR 1.54, 95% CI 1.1-2.15), chronic heart disease (OR 1.49, 95% CI 1.01-2.22) and infection caused by serotypes 3 (OR 1.97, 95% CI 1.23-3.16), 19A (OR 2.34, 95% CI 1.14-4.42) and 19F (OR 3.55, 95% CI 1.22-10.28). In conclusion, respiratory failure is a frequent complication of pneumococcal pneumonia and causes high morbidity and mortality. Pneumococcal serotypes 3, 19A and 19F are the main risk factors for this complication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23845720     DOI: 10.1183/09031936.00050413

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and ≥ 60 years in Bogota, Colombia.

Authors:  Aura Lucia Leal Castro; Germán Camacho-Moreno; Anita Montañez-Ayala; Fabio Varón-Vega; José Camilo Alvarez-Rodríguez; Sandra Valderrama-Beltrán; Beatriz Elena Ariza; Oscar Pancha; Ana Yadira Santana; Nella Sánchez Flórez; Patricia Reyes; Jaime Ruiz; Claudia Beltran; Emilia Prieto; Monica Rojas; Juan Urrego-Reyes; Cintia Irene Parellada
Journal:  IJID Reg       Date:  2022-04-28

2.  Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study.

Authors:  Jean-Pierre Bedos; Emmanuelle Varon; Raphael Porcher; Pierre Asfar; Yves Le Tulzo; Bruno Megarbane; Armelle Mathonnet; Anthony Dugard; Anne Veinstein; Kader Ouchenir; Shidasp Siami; Jean Reignier; Arnaud Galbois; Joël Cousson; Sébastien Preau; Olivier Baldesi; Jean-Philippe Rigaud; Bertrand Souweine; Benoit Misset; Frederic Jacobs; Florent Dewavrin; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2018-11-19       Impact factor: 17.440

3.  Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease.

Authors:  J Burgos; M N Larrosa; A Martinez; J Belmonte; J González-López; J Rello; T Pumarola; A Pahissa; V Falco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-12       Impact factor: 3.267

Review 4.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 5.  Epidemiology, virulence factors and management of the pneumococcus.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Res       Date:  2016-09-14

Review 6.  Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement.

Authors:  William P Hausdorff; William P Hanage
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study.

Authors:  Luis A Ruiz; Pedro P España; Ainhoa Gómez; Amaia Bilbao; Carmen Jaca; Amaia Arámburu; Alberto Capelastegui; Marcos I Restrepo; Rafael Zalacain
Journal:  BMC Geriatr       Date:  2017-06-20       Impact factor: 3.921

8.  Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain.

Authors:  Jordi Càmara; José María Marimón; Emilia Cercenado; Nieves Larrosa; María Dolores Quesada; Dionísia Fontanals; Meritxell Cubero; Emilio Pérez-Trallero; Asunción Fenoll; Josefina Liñares; Carmen Ardanuy
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

9.  The relevance of pneumococcal serotypes.

Authors:  Chamira Rodrigo; Wei Shen Lim
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 10.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.

Authors:  Antoni Torres; Francesco Blasi; Nathalie Dartois; Murat Akova
Journal:  Thorax       Date:  2015-07-28       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.